¡¡ ¡¾²Î¿¼ÎÄÏס¿

  ¡¡1 Congdon N, O¬ðColmain B, Klaver CC, Klein R, Munoz B, Friedman DS, Kempen J, Taylor HR, Mitchell P. Eye Diseases Prevalence Research Group.Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol,2004;22:477ª²485

¡¡¡¡2³Âɺ,½ðΰ,ãÉƽ,½ºË.Ѫ¹ÜÄÚƤÉú³¤Òò×Ó¼Ò×å¼°ÆäÊÜÌåÓëÖ×ÁöѪ¹ÜÉú³ÉÑо¿½øÕ¹.ÉúÃü¿Æѧ,2004;16:19ª²23

¡¡¡¡3 Adamis AP, Miller JW, Bernal MT, D¬ðAmico DJ, Folkman J, Yeo TK, Yeo KT. Increased vascular endothelia growth factor leves in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol,1994;118:445ª²450

¡¡¡¡4 Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen HV, Aiello LM, Ferrara N, King GL. Vascular endothelia growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med,1994;331:1480ª²1487

¡¡¡¡5 Malecaze F, Clamens S, Simorreª²Pinatel V, Mathis A, Chollet P, Favard C, Bayard F, Plouet J. Detection of vascular endothelia growth factor messenger RNA and vascular endothelia growth factorª²liker activity in proliferative diabetic retinopathy. Arch Ophthalmol,1994;112:1476ª²1482

¡¡¡¡6 Kvanta A, Algvere PV, Berglin L. Subfoveal fibrovascular membranes in ageª²related macular degeneration express vascular endothelia growth factor.
Invest Ophthalmol Vis Sci,1996;37:1929ª²1934

¡¡¡¡7 Moravski CJ, Skinner SL, Stubbs AJ, Sarlos S, Kelly DJ, Cooper ME, Gilbert RE, Wilkinsonª²Berka JL. The renninª²angiotensin system influnces ocular endothelial cell proliferation in diabetes:transgenic and interventional studies. Am J Pathol,2003;161:151ª²160

¡¡¡¡8 Gragoudas ES, Adamis AP, Cunmingham ET Jr, Feinsod M, Guyer DR. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovasclar ageª²related macular degeneration. N Engl J Med,2004;351:2805ª²2816

¡¡¡¡9 Cunningham ET Jr, Adamis AP, Altaweel M, Aiello LP, Bressler NM, D¬ðAmico DJ£¬ Goldbaum M, Guyer DR, Katz B, Patel M, Schwartz StD. Macugen Diabetic Retinopathy Study Group.A phase II randomized doubleª²masked trial of pegaptanib, an antiª²vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology,2005;112:1747ª²1757

¡¡¡¡10 Gonzales CR. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Enhanced efficacy associated with early treatment of neovascular ageª²related macular degeneration with pegaptanib sodium: an exploratory analysis. Retina,2005;25:815ª²827

¡¡¡¡11 VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Chakravarthy U. Adamis AP. Cunningham ET Jr, Goldbaum M, Guyer DR, Katz B, Patel M. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular ageª²related macular degeneration.Ophthalmology,2006;113:1508.e1ª²25

ÉÏÒ»Ò³  [1] [2] [3]